Advertise on podcast: Healthcare Unfiltered Express

The World Congress on Lung Cancer in Seoul has just concluded, and the insightful Dr. Chul Kim of Georgetown University and Medstar Health joined #HealthcareUnfiltered EXPRESS to share his valuable opinions on practice changing/informing data presented at the meeting. Please share, subscribe, and join the conversation.

Pranav Rajpurkar, co-founder of A2Z Radiology, joins Healthcare Unfiltered EXPRESS to discuss the current—and future—state of AI in radiology. How will AI transform the field? What will it mean for radiologists, physicians, and patients? And where is all of this headed? With AI reshaping nearly every corner of healthcare, this is a conversation you won’t want to miss. Listen, share, rate, and please subscribe!

Dr. Gilberto Lopes, senior author on a recent Lancet publication addressing alcohol and cancer, joins the show to share the findings of hs group research, and the broader implications of alcohol and various cancers. Is there a safe level for alcohol use? What cancers might alcohol cause? What are the proper recommendations for patients? All of this and more on this new episode of Healthcare Unfiltered EXPRESS. Please share, subscribe, and join the conversation. Read the article. https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(26)00229-2/fulltext

Dr. Bishoy Flatas, a pioneer in bladder cancer research at Cornell, joins the show to highlight his work on AI Tumor Twins and his in-silico model for predicting which drugs may be more effective for certain bladder cancers, optimizing clinical trial execution. Bishoy was recently interviewed on CBS News, and that segment garnered over 22 million views. This is a must listen from this innovator and trailblazer. Please share, subscribe, and join the conversation. Link to CBS News: https://x.com/CBSNews/status/2083295365353107461

I am joined by the amazing Dr. Paul Richardson from the Dana-Farber Cancer Institute to discuss the SUCCESSOR trial that was presented at EHA. This trial discusses CELMoDs by highlighting a landmark randomized Phase 3 clinical study evaluating the oral medication mezigdomide combined with carfilzomib and dexamethasone (MeziKd) versus carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma. Results show the regimen significantly improves progression-free survival. Dr. Richardson puts this data into perspective. A must-watch on YouTube and listen here

Dr. Bruna Pellini of Baptist Health Miami Cancer Institute joins Healthcare Unfiltered EXPRESS to break down the most important lung cancer data presented at ASCO 2026. Together, we discuss the trials most likely to influence clinical practice, what they mean for patients today, and how they may reshape future treatment decisions. Watch on YouTube, subscribe, share, review, and join the conversation.

Hot off the press, the ENDURANCE trial was JUST published in NEJM. This trial explored whether patients with newly diagnosed myeloma benefit from long-term maintenance lenalidomide versus 2-years only. Dr. Vincent Rajkumar, senior author on the paper, shares the findings and context. Please subscribe, share, and join the conversation.

Dr. Amer Zeidan joins the Healthcare Unfiltered EXPRESS to discuss the recently published KOMET-007 trial, which made its way to print in Blood. Dr. Zeidan discusses how Menin inhibitors are transforming how we approach AML like no other therapies before. What does the future hold and how will the results of this trial affect therapy? The KOMET-007 trial is a Phase 1/2 clinical study evaluating the targeted Menin inhibitor ziftomenib in combination with standard-of-care chemotherapies for acute myeloid leukemia (AML) patients with NPM1 mutations or KMT2A rearrangements.  A must listen - please share subscribe, and join the conversation.

On this Healthcare Unfiltered EXPRESS, Dr. Arturo Bonilla, CMO of Massive Bio and an AI oncologist expert who leads many AI efforts nationally, joined Chadi to provide his insights on where AI is being applied in patient care. He gives timely use case examples that will resonate with everyone. AI is here to stay and we must know where and how it applies. Please join the conversation, subscribe, like, comment, and write a review.

Dr. Virginia Kaklamani joins Healthcare Unfiltered EXPRESS to discuss the recent FDA-approved indications for T-DXd in breast cancer, and what this means for treating patients with the disease. A critical episode ahead of the annual ASCO meeting. Check it out, subscribe, rate, review, and join the conversation.

Dr. Rani Bansal of Duke University joins the show to share her insights on the latest ESMO Breast meeting that concluded in Berlin. Dr. Rani shares data on the top 5 abstracts that may change or inform practice. Check it out, share, subscribe, and join the conversation.

Dr. Emily Landon of the University of Chicago joins the show to explain everything you must know about the Hantavirus - should we be concerned? What to do? What not to do? Is this another COVID? Get the facts right here, and please share, subscribe, and join the conversation.

Dr. Deva Mahalingam shares on Healthcare Unfiltered EXPRESS a new paper published in Nature Medicine on a regimen showing significant promise in pancreatic cancer. You want to listen to this podcast and check out the paper. https://www.nature.com/articles/s41591-026-04327-4 Share, subscribe, and join the conversation.

Dr. Matt Davids of the Dana Farber Cancer Institute joins Healthcare Unfiltered EXPRESS to share his data-solidified insights on navigating the treatment of relapsed/refractory (R/R) CLL, considering the welcome advances the field has witnessed in treating front-line disease. Check it out, subscribe, rate, and join the conversation.

Dr. Vincent Rajkumar of the Mayo Clinic joins the Healthcare Unfiltered EXPRESS to highlight a major study recently published in the NEJM concerning patients with R/R multiple myeloma. This study is arguably changing the standard of care for relapsed disease. We discussed the study, its rationale, its implications, and limitations. Here is a link to the actual publication: https://www.nejm.org/doi/full/10.1056/NEJMoa2514663 Please subscribe, rate, share, review, and join the conversation.